Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

The Ebola outbreak in the Democratic Republic of Congo (DRC) has crossed 4,000 cases, making it the second-largest Ebola epidemic ever recorded after the 2014-2016 West Africa outbreak.

According to the latest Health Ministry situation report, the DRC has recorded 4,053 cases and 1,850 deaths since the outbreak was officially declared in mid-May. Health officials believe transmission may have begun as early as January.

The outbreak is caused by the Bundibugyo strain of the Ebola virus, which has neither a vaccination nor any antiviral. However, two vaccine candidates by Oxford-SII and Moderna have entered clinical trials.

Africa CDC Calls for Intensified Response

Africa's public health agency has said the current response needs to be significantly expanded, announcing plans to shift from traditional contact tracing to an active, community-wide search for cases.

Dr. Wessam Mankoula, Acting Head of Emergency Preparedness and Response at the Africa Centres for Disease Control and Prevention (Africa CDC), said response teams will begin door-to-door case finding.

"I think the time for incremental action is over and we're starting now the phase for scaling up," he said.

He explained that community health workers would move from house to house to identify people showing Ebola symptoms rather than relying solely on contact tracing.

Africa CDC Director General Dr. Jean Kaseya also outlined plans for a village-centered response, with greater community involvement, expanded use of digital surveillance tools, and stronger interventions in camps housing people displaced by conflict.

Second-Largest Ebola Outbreak on Record

The outbreak has spread across 53 health zones in the provinces of Ituri, North Kivu, South Kivu, Haut-Uele and Tshopo.

Ituri, the epicentre of the outbreak, accounts for 86.9% of confirmed cases.

Africa CDC noted that, 11 weeks into the outbreak, the DRC has reported eight times more cases and six times more deaths than were recorded at the same stage of the 2014 West Africa Ebola epidemic, which ultimately infected more than 28,000 people and killed at least 11,000.

Is The Bundibugyo Virus Mutating?

Health officials are now examining whether changes in the virus could be contributing to the unusually severe outbreak.

Speaking at a press briefing, Dr. Jean Kaseya said he had discussed the situation with World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus.

"We plan studies to check if there is no additional issue, or maybe if the virus is not mutating, because the level of severity of this Bundibugyo outbreak is unprecedented," Kaseya said.

He cautioned against assuming scientists fully understand the virus.

"After many Ebola outbreaks, we cannot assume we know everything. In the DRC, we must listen to communities, act on what they tell us and build the trust needed to stop transmission."

Outbreak Shows No Signs Of Slowing

Medical charity Médecins Sans Frontières (MSF) said the response is expanding but is still not reaching communities quickly enough to interrupt transmission, The Guardian reported.

Philippa Boulle, MSF's Deputy Medical Director, warned that the outbreak continues to spread into new areas.

"New suspected cases are being reported almost daily in new locations, outside already identified transmission chains. To prevent further loss of life, the response must outpace the current rate of transmission," Boulle said.

Kaseya also highlighted shortcomings in surveillance, noting that only 10 contacts are being identified per Ebola patient, compared with the approximately 40 contacts typically expected during effective contact tracing.

The US Food and Drug Administration (FDA) has granted accelerated approval to Replimune's Tudriqev for the treatment of advanced refractory melanoma—a deadly form of skin cancer that continues to grow or spread despite treatment with standard immunotherapy drugs such as PD-1 inhibitors.

The approval comes after the FDA rejected the therapy twice over concerns related to the quality of clinical data.

The latest decision was supported by clinical trial results showing that 24% of patients responded to treatment, with responses lasting a median of 14.1 months. The FDA also considered input from clinical experts and patient advocates, who highlighted the urgent need for new treatment options for patients with refractory melanoma.

What Is Tudriqev?

Tudriqev is an oncolytic viral immunotherapy based on a genetically modified herpes simplex virus type 1 (HSV-1). The virus is engineered to selectively infect and destroy cancer cells while stimulating the body's immune system to recognize and attack the tumour.

The therapy is approved in combination with nivolumab for adults with unresectable melanoma that:

• Has spread or cannot be safely removed through surgery.
• Has progressed after treatment with a PD-1-blocking antibody-based regimen.

"For patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited. Clinicians managing these patients know this urgency firsthand," said Karim Mikhail, Acting Director of the FDA's Center for Biologics Evaluation and Research (CBER).

Also read: Narcolepsy: US FDA Approves First-Ever Pill That Targets Root Cause of Rare Sleep Disorder

How Does Tudriqev Work?

Tudriqev is injected directly into tumours, where the modified virus replicates inside cancer cells, causing them to rupture. At the same time, it activates the immune system to identify and attack cancer cells throughout the body.

When combined with nivolumab, an anti-PD-1 immunotherapy, Tudriqev may help restore an anti-tumour immune response in patients whose melanoma no longer responds to checkpoint inhibitor therapy.

How Is The Treatment Given?

Tudriqev is administered once every two weeks for eight consecutive doses.

• The dose is determined by tumour size.
• A lower concentration is used for the first injection, followed by a higher concentration for the remaining doses.
• Nivolumab is administered intravenously starting in week three of treatment.

Replimune has announced a list price of $450,000 per course of therapy, before rebates and discounts.

Clinical trial results

The FDA based its approval on an open-label, multiregional, single-arm trial involving 140 adults with Stage IIIB, IIIC, or IV unresectable melanoma whose disease progressed after at least eight consecutive weeks of prior anti-PD-1 therapy.

Among the 91 evaluable patients:

• 24% achieved an objective response.
• The median duration of response was 14.1 months.

A confirmatory Phase III study is currently underway to verify the drug's clinical benefit. Replimune expects results in 2030.

Safety and Side Effects

The most common side effects reported in more than 10% of patients included:

• Fatigue
• Fever (pyrexia)
• Infections
• Chills
• Musculoskeletal pain
• Nausea and Vomiting
• Diarrhoea
• Injection-site reactions
• Headache
• Cough
• Influenza-like illness
• Rash
• Shortness of breath (dyspnoea)
• Bleeding (haemorrhage)
• Oedema
• Abdominal pain

The FDA also warned of:

• The risk of accidental transmission of herpes infection to close contacts.
• Development or reactivation of herpes infection in treated patients.
• Injection-related complications.

About melanoma

Melanoma is the deadliest form of skin cancer and the fifth most common cancer in the United States. An estimated 105,000 new cases are expected to be diagnosed in the US in 2025, with the disease causing nearly 8,500 deaths each year.

Immune checkpoint inhibitors are the current standard treatment for advanced melanoma, but about half of patients either do not respond or eventually develop resistance, underscoring the need for new treatment options such as Tudriqev.

The US Food and Drug Administration (FDA) has approved Orzeyful (oveporexton), the first oral treatment for adults with narcolepsy type 1 that targets the underlying cause of the disorder rather than just managing its symptoms.

Developed by Takeda, Orzeyful is the first approved therapy to act on the orexin system, restoring the signaling lost in people with narcolepsy type 1. Existing treatments primarily help control symptoms such as excessive daytime sleepiness or cataplexy but do not address the disease mechanism.

What Is Narcolepsy Type 1?

Narcolepsy type 1 is a rare, lifelong neurological disorder that affects the brain's ability to regulate sleep and wakefulness. It impacts about 1 in 2,000 people in the United States.

The condition occurs when brain cells that produce orexin—a neurotransmitter essential for maintaining wakefulness, regulating sleep, and controlling muscle tone—are lost.

Common symptoms include:

• Excessive daytime sleepiness
• Cataplexy (sudden muscle weakness triggered by strong emotions)
• Sleep paralysis
• Hallucinations during the transition between sleep and wakefulness
• Disrupted nighttime sleep

Also read: FDA Approves Moderna's First mRNA Flu Vaccine, Marking A Milestone In Influenza Prevention

How Does Orzeyful Work?

Orzeyful is a twice-daily oral tablet that activates the orexin receptor, helping restore the missing orexin signaling in patients with narcolepsy type 1.

Unlike stimulants or sedatives that only relieve symptoms, the drug targets the biological cause of the disorder.

Clinical Trial Findings

The FDA approval was supported by two randomized, double-blind, placebo-controlled Phase III studies involving 273 adults with narcolepsy type 1 over 12 weeks.

Patients treated with Orzeyful 2 mg experienced:

• Improved ability to stay awake during the day
• Reduced excessive daytime sleepiness
• Fewer cataplexy episodes
• Improvements in sleep paralysis
• Reduced hallucinations during sleep-wake transitions
• Better nighttime sleep quality

Safety And Side Effects

The most commonly reported side effects were:

• Insomnia
• Increased urinary frequency
• Urinary urgency
• Increased saliva production

Read More: Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748

Few participants discontinued treatment because of side effects.

Orzeyful should not be taken with strong CYP3A inhibitors, and its safety and effectiveness have not been established in patients under 18 years of age.

The FDA has recommended scheduling the drug under the Controlled Substances Act. It can be commercially launched once the US Drug Enforcement Administration (DEA) completes the scheduling process.

Narcolepsy Treatment Landscape

According to an analysis by marketing firm Global Data:

• An estimated 735,082 people were living with diagnosed narcolepsy worldwide in 2024, with cases projected to rise to 761,297 by 2029.
• Generic medicines, with limited innovative therapies available, dominate the current narcolepsy treatment market.
• The development pipeline includes 28 drug candidates, comprising five Phase III and four Phase II assets, with no therapies currently in the pre-registration stage.
• More than 115 clinical trials have been conducted in narcolepsy over the past decade.